scholarly journals Ethical and Bioethical Aspects in the Use of Stem Cells in Chronic Spinal Cord Injuries

2022 ◽  
Vol 10 (1) ◽  
pp. 01-04
Author(s):  
Pedro Rolando López Rodríguez ◽  
Alberto Benitez Herrera

One of the fundamental dogmas maintained in neuroscience until the last century held that regeneration of the nervous system cannot occur in stages of adult life. However, it has been shown in several species during the postnatal stage and throughout life, that new neurons continue to be generated in some places in the human body. Objectives: The research was: to evaluate ethical and bioethical aspects in patients who were treated with an autologous stem cell implant in chronic spinal cord injuries. Method. An analysis is made of the ethical aspects that accompany the implantation of autologous stem cells in chronic spinal cord injuries. The results are evaluated at the "Enrique Cabrera" Surgical Clinical Teaching Hospital. Results: Ethical dilemmas are expressed and that have, among their relevant principles, the inviolability of human life. In higher animals, stem cells according to their evolutionary state can be embryonic and somatic or adult. Currently there is an extraordinary controversy about which stem cells to use from embryonic or adult ones, a debate in which both scientific, ethical, religious, social and political aspects have been included. One aspect of the scientific debate is related to the generative capacity of tumors by embryonic cells. From the ethical point of view, it has been argued that the use of human embryonic stem cells implies the destruction of embryos and it has been considered that life begins at the same moment of the union of the sperm with the ovum and that this would be equivalent to the destruction of a human life which would not be justifiable. Others do not agree with these criteria and argue that their use to save lives through research or therapy would be justified. Conclusions The physical disability produced by a chronic spinal cord injury raises an ethical dilemma about the use of stem cells, anticipating that the main controversy about this action has to do fundamentally with the way in which they are obtained.

2020 ◽  
Vol 15 (4) ◽  
pp. 321-331 ◽  
Author(s):  
Zhe Gong ◽  
Kaishun Xia ◽  
Ankai Xu ◽  
Chao Yu ◽  
Chenggui Wang ◽  
...  

Spinal Cord Injury (SCI) causes irreversible functional loss of the affected population. The incidence of SCI keeps increasing, resulting in huge burden on the society. The pathogenesis of SCI involves neuron death and exotic reaction, which could impede neuron regeneration. In clinic, the limited regenerative capacity of endogenous cells after SCI is a major problem. Recent studies have demonstrated that a variety of stem cells such as induced Pluripotent Stem Cells (iPSCs), Embryonic Stem Cells (ESCs), Mesenchymal Stem Cells (MSCs) and Neural Progenitor Cells (NPCs) /Neural Stem Cells (NSCs) have therapeutic potential for SCI. However, the efficacy and safety of these stem cellbased therapy for SCI remain controversial. In this review, we introduce the pathogenesis of SCI, summarize the current status of the application of these stem cells in SCI repair, and discuss possible mechanisms responsible for functional recovery of SCI after stem cell transplantation. Finally, we highlight several areas for further exploitation of stem cells as a promising regenerative therapy of SCI.


2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Jack Rosner ◽  
Pablo Avalos ◽  
Frank Acosta ◽  
John Liu ◽  
Doniel Drazin

Any traumatic spinal cord injury (SCI) may cause symptoms ranging from pain to complete loss of motor and sensory functions below the level of the injury. Currently, there are over 2 million SCI patients worldwide. The cost of their necessary continuing care creates a burden for the patient, their families, and society. Presently, few SCI treatments are available and none have facilitated neural regeneration and/or significant functional improvement. Research is being conducted in the following areas: pathophysiology, cellular therapies (Schwann cells, embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, olfactory ensheathing cells), growth factors (BDNF), inhibitory molecules (NG2, myelin protein), and combination therapies (cell grafts and neurotrophins, cotransplantation). Results are often limited because of the inhibitory environment created following the injury and the limited regenerative potential of the central nervous system. Therapies that show promise in small animal models may not transfer to nonhuman primates and humans. None of the research has resulted in remarkable improvement, but many areas show promise. Studies have suggested that a combination of therapies may enhance results and may be more effective than a single therapy. This paper reviews and discusses the most promising new SCI research including combination therapies.


2015 ◽  
Vol 2015 ◽  
pp. 1-24 ◽  
Author(s):  
Rita C. Assunção-Silva ◽  
Eduardo D. Gomes ◽  
Nuno Sousa ◽  
Nuno A. Silva ◽  
António J. Salgado

Spinal cord injury (SCI) is a central nervous system- (CNS-) related disorder for which there is yet no successful treatment. Within the past several years, cell-based therapies have been explored for SCI repair, including the use of pluripotent human stem cells, and a number of adult-derived stem and mature cells such as mesenchymal stem cells, olfactory ensheathing cells, and Schwann cells. Although promising, cell transplantation is often overturned by the poor cell survival in the treatment of spinal cord injuries. Alternatively, the therapeutic role of different cells has been used in tissue engineering approaches by engrafting cells with biomaterials. The latter have the advantages of physically mimicking the CNS tissue, while promoting a more permissive environment for cell survival, growth, and differentiation. The roles of both cell- and biomaterial-based therapies as single therapeutic approaches for SCI repair will be discussed in this review. Moreover, as the multifactorial inhibitory environment of a SCI suggests that combinatorial approaches would be more effective, the importance of using biomaterials as cell carriers will be herein highlighted, as well as the recent advances and achievements of these promising tools for neural tissue regeneration.


2005 ◽  
Vol 27 (8) ◽  
pp. 812-819 ◽  
Author(s):  
Hajime Kimura ◽  
Masahide Yoshikawa ◽  
Ryousuke Matsuda ◽  
Hayato Toriumi ◽  
Fumihiko Nishimura ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3214
Author(s):  
Krisztián Pajer ◽  
Tamás Bellák ◽  
Antal Nógrádi

Hundreds of thousands of people suffer spinal cord injuries each year. The experimental application of stem cells following spinal cord injury has opened a new era to promote neuroprotection and neuroregeneration of damaged tissue. Currently, there is great interest in the intravenous administration of the secretome produced by mesenchymal stem cells in acute or subacute spinal cord injuries. However, it is important to highlight that undifferentiated neural stem cells and induced pluripotent stem cells are able to adapt to the damaged environment and produce the so-called lesion-induced secretome. This review article focuses on current research related to the secretome and the lesion-induced secretome and their roles in modulating spinal cord injury symptoms and functional recovery, emphasizing different compositions of the lesion-induced secretome in various models of spinal cord injury.


2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Junhao Deng ◽  
Yiling Zhang ◽  
Yong Xie ◽  
Licheng Zhang ◽  
Peifu Tang

Spinal cord injury (SCI) is an intractable and worldwide difficult medical challenge with limited treatments. Neural stem/progenitor cell (NS/PC) transplantation derived from fetal tissues or embryonic stem cells (ESCs) has demonstrated therapeutic effects via replacement of lost neurons and severed axons and creation of permissive microenvironment to promote repair of spinal cord and axon regeneration but causes ethnical concerns and immunological rejections as well. Thus, the implementation of induced pluripotent stem cells (iPSCs), which can be generated from adult somatic cells and differentiated into NS/PCs, provides an effective alternation in the treatment of SCI. However, as researches further deepen, there is accumulating evidence that the use of iPSC-derived NS/PCs shows mounting concerns of safety, especially the tumorigenicity. This review discusses the tumorigenicity of iPSC-derived NS/PCs focusing on the two different routes of tumorigenicity (teratomas and true tumors) and underlying mechanisms behind them, as well as possible solutions to circumvent them.


Sign in / Sign up

Export Citation Format

Share Document